Digestive Diseases and Sciences

, Volume 59, Issue 10, pp 2529–2535 | Cite as

Mucosal Healing Predicts the Long-Term Prognosis of Intestinal Behçet’s Disease

  • Sun Mie Yim
  • Duk Hwan Kim
  • Hyun Jung Lee
  • Hui Won Jang
  • Soo Jung Park
  • Sung Pil Hong
  • Tae Il Kim
  • Won Ho Kim
  • Jae Hee CheonEmail author
Original Article



Mucosal healing (MH) has emerged as a therapeutic goal in the treatment of inflammatory bowel disease; however, little is known about the impact of MH on the prognosis of intestinal Behçet’s disease (BD).


We investigated whether MH could predict the prognosis of intestinal BD.


We retrospectively reviewed the medical records of 80 patients with intestinal BD who underwent colonoscopy within 3 months after clinical remission. The clinical recurrence rate according to the presence or absence of MH was evaluated using the Kaplan–Meier method and the log-rank test. In order to evaluate MH as an independent prognostic factor, a multivariate analysis using Cox proportional hazards regression model was performed including other potential factors for the relapse of intestinal BD.


The number of patients with active ulcers at the time of clinical remission was 57 (71.3 %), while 23 patients (28.7 %) were experiencing MH. In the active ulcer group, 39 patients (68.4 %) experienced recurrence during the follow-up period, whereas 7 patients (30.4 %) recurred in the MH group. The cumulative recurrence rate was significantly higher in the active ulcer group than in the MH group (P < 0.001). A multivariate analysis identified active ulcers at the time of clinical remission as an independent predictive factor for relapse.


Our study demonstrates that MH is an independent factor predictive of long-term prognosis of intestinal BD. MH might be the ultimate therapeutic goal in the treatment of intestinal BD.


Intestinal Behçet’s disease Mucosal healing Inflammatory bowel disease 



This work was supported by a Grant of the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (Grant Number A111428), the “Kiturami” Faculty Research Assistance Program of Yonsei University College of Medicine for 2012 (6-2012-0150), a faculty research Grant of Yonsei University College of Medicine for 2012(6-2012-0135 and 6-2012-0163), and a Grant of the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (Grant Number A120176).

Conflict of interest



  1. 1.
    James DG. Behcet’s syndrome. N Engl J Med. 1979;301:431–432.PubMedCrossRefGoogle Scholar
  2. 2.
    Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet’s disease. Semin Arthritis Rheum. 1998;27:197–217.PubMedCrossRefGoogle Scholar
  3. 3.
    Kasahara Y, Tanaka S, Nishino M, et al. Intestinal involvement in Behcet’s disease: review of 136 surgical cases in the Japanese literature. Dis Colon Rectum. 1981;24:103–106.PubMedCrossRefGoogle Scholar
  4. 4.
    Baba S, Maruta M, Ando K, et al. Intestinal Behcet’s disease: report of five cases. Dis Colon Rectum. 1976;19:428–440.PubMedCrossRefGoogle Scholar
  5. 5.
    Bayraktar Y, Ozaslan E, Van Thiel DH. Gastrointestinal manifestations of Behcet’s disease. J Clin Gastroenterol. 2000;30:144–154.PubMedCrossRefGoogle Scholar
  6. 6.
    Sakane T, Takeno M, Suzuki N, et al. Behcet’s disease. N Engl J Med. 1999;341:1284–1291.PubMedCrossRefGoogle Scholar
  7. 7.
    Ebert EC. Gastrointestinal manifestations of Behcet’s disease. Dig Dis Sci. 2009;54:201–207.PubMedCrossRefGoogle Scholar
  8. 8.
    Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis. 2009;15:1295–1301.PubMedCrossRefGoogle Scholar
  9. 9.
    Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–1201.PubMedCrossRefGoogle Scholar
  10. 10.
    Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc. 2006;63:433–442.; quiz 464.PubMedCrossRefGoogle Scholar
  11. 11.
    Allez M, Lemann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol. 2010;16:2626–2632.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    van Assche G, Vermeire S, Rutgeerts P. Mucosal healing and anti TNFs in IBD. Curr Drug Targets. 2010;11:227–233.PubMedCrossRefGoogle Scholar
  13. 13.
    Cheon JH, Kim WH. Recent advances of endoscopy in inflammatory bowel diseases. Gut Liver. 2007;1:118–125.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behcet’s disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol. 2009;104:2492–2499.PubMedCrossRefGoogle Scholar
  15. 15.
    Lee CR, Kim WH, Cho YS, et al. Colonoscopic findings in intestinal Behcet’s disease. Inflamm Bowel Dis. 2001;7:243–249.PubMedCrossRefGoogle Scholar
  16. 16.
    Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet’s disease. Inflamm Bowel Dis. 2011;17:605–613.PubMedCrossRefGoogle Scholar
  17. 17.
    Kim JS, Lim SH, Choi IJ, et al. Prediction of the clinical course of Behcet’s colitis according to macroscopic classification by colonoscopy. Endoscopy. 2000;32:635–640.PubMedCrossRefGoogle Scholar
  18. 18.
    Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7:15–29.PubMedCrossRefGoogle Scholar
  19. 19.
    D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–786.PubMedCrossRefGoogle Scholar
  20. 20.
    D’Haens GR, Fedorak R, Lemann M, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn’s disease. Inflamm Bowel Dis. 2009;15:1599–1604.PubMedCrossRefGoogle Scholar
  21. 21.
    Lee HW, Kim WH, Cheon JH. The medical treatments of intestinal Behçet’s disease: an update. Intest Res. 2013;11:155–160.CrossRefGoogle Scholar
  22. 22.
    Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102–1111. e1102.PubMedCrossRefGoogle Scholar
  23. 23.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.PubMedCrossRefGoogle Scholar
  24. 24.
    Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.PubMedCrossRefGoogle Scholar
  25. 25.
    Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012;18:1634–1640.PubMedCrossRefGoogle Scholar
  26. 26.
    Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn’s disease. Inflamm Bowel Dis. 2009;15:375–382.PubMedCrossRefGoogle Scholar
  27. 27.
    D’Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn’s (ileo-) colitis with azathioprine. Gastrointest Endosc. 1999;50:667–671.PubMedCrossRefGoogle Scholar
  28. 28.
    Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47–53.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–1635.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Sun Mie Yim
    • 1
  • Duk Hwan Kim
    • 1
  • Hyun Jung Lee
    • 1
  • Hui Won Jang
    • 1
  • Soo Jung Park
    • 1
  • Sung Pil Hong
    • 1
  • Tae Il Kim
    • 1
    • 2
  • Won Ho Kim
    • 1
    • 2
  • Jae Hee Cheon
    • 1
    • 2
    Email author
  1. 1.Department of Internal Medicine and Institute of GastroenterologyYonsei University College of MedicineSeoulKorea
  2. 2.Brain Korea 21 Project for Medical ScienceYonsei UniversitySeoulKorea

Personalised recommendations